Compounds > nafimidone
Page last updated: 2024-09-22

nafimidone

Description

nafimidone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51200
CHEMBL ID416801
SCHEMBL ID1817018
MeSH IDM0116271

Synonyms (27)

Synonym
2-imidazol-1-yl-2'-acetonaphthone
2-(1h-imidazol-1-yl)-1-(1-naphthalenyl)ethanone
nafimidonum [latin]
1-(2-naphthoylmethyl)imidazole
nafimidone
brn 0523776
ethanone, 2-(1h-imidazol-1-yl)-1-(1-naphthalenyl)-
nafimidone [inn]
nafimidona [spanish]
CHEMBL416801
2-imidazol-1-yl-1-naphthalen-2-ylethanone
hzu3iq1eww ,
64212-22-2
nafimidonum
5-23-04-00380 (beilstein handbook reference)
unii-hzu3iq1eww
nafimidona
nafimidone [mart.]
ITPVLJQRUQVNSD-UHFFFAOYSA-N
SCHEMBL1817018
DTXSID80214426
1-(1-naphthyl)-2-(1h-imidazol-1-yl)ethanone
FT-0768480
1-(2-naphthyl)-2-(imidazol-1-yl)ethanone
Q6958175
2-(1h-imidazol-1-yl)-1-(naphthalen-2-yl)ethan-1-one
EN300-18563699

Research Excerpts

Overview

ExcerptReference
"Nafimidone is a new antiepileptic drug which may be effective in partial onset seizures. "( Gunawan, S; Treiman, DM, 1987)

Bioassays (9)

Assay IDTitleYearJournalArticle
AID112801Effective dose in mice by horizontal screen assay (administered orally); No effect at highest dose of 400 mg/kg1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID40680In vitro displacement of [3H]flunitrazepam binding to cortical membranes at 5e-5M concentration1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID112168Effective dose to produce anticonvulsant activity using maximal electroshock assay (MES) evaluated in mice after oral administration1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Imidazole anticonvulsants: structure-activity relationships of [(biphenylyloxy)alkyl]imidazoles.
AID112808Effective dose in mice by pentylenetetrazole assay (administered subcutaneously)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID119413Potentiation of hexobarbital-induced sleeping time in mice1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID1312151Anticonvulsant activity in patient assessed as improvement in seizure control at 600 mg/day administered up to 1 year2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
AID40681In vivo displacement of [3H]flunitrazepam binding to rat cortical membranes after 20 mg/kg ip dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID122339Compound was tested for time to peak anticonvulsant effect (TPE)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
AID112804Effective dose in mice by maximal electroshock assay, administered orally1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Structure-activity relationships of (arylalkyl)imidazole anticonvulsants: comparison of the (fluorenylalkyl)imidazoles with nafimidone and denzimol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (50.00)18.7374
1990's3 (18.75)18.2507
2000's1 (6.25)29.6817
2010's3 (18.75)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.35%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
phenytoin[no description available]medium50imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
denzimol[no description available]medium30
valproic acid[no description available]medium10branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
felbamate[no description available]medium10carbamate esteranticonvulsant;
neuroprotective agent
sec-butyl-propylacetamide[no description available]medium10
naphazoline[no description available]medium210naphthalenes
carbamazepine[no description available]medium40dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
27-hydroxycholesterol[no description available]medium1026-hydroxycholesterolapoptosis inducer;
human metabolite;
mouse metabolite;
neuroprotective agent
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
nafimidone alcohol[no description available]medium30
ethylmorphine[no description available]medium10morphinane alkaloid
aniline[no description available]medium10anilines;
primary arylamine
diazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
carbamazepine epoxide[no description available]medium10dibenzoazepine;
epoxide;
ureas		allergen;
drug metabolite;
marine xenobiotic metabolite
flunitrazepam[no description available]medium101,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes		anxiolytic drug;
GABAA receptor agonist;
sedative
hexobarbital[no description available]medium10barbiturates
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure0low60
Absence Seizures0low60
Atonic Absence Seizure0low60
Atonic Absence Seizures0low60
Atonic Seizure0low60
Atonic Seizures0low60
Aura0low20
Awakening Epilepsy0low20
Chronic Disease0low10
Chronic Illness0low10
Chronically Ill0low10
Clonic Seizure0low60
Clonic Seizures0low60
Complex Partial Seizure0low60
Complex Partial Seizures0low60
Convulsion0low60
Convulsion, Non-Epileptic0low60
Convulsions0low60
Convulsive Seizure0low60
Convulsive Seizures0low60
Disease Models, Animal0low10
Epilepsy0low20
Epilepsy, Cryptogenic0low20
Epileptic Seizure0low60
Epileptic Seizures0low60
Generalized Absence Seizure0low60
Generalized Absence Seizures0low60
Generalized Tonic-Clonic Seizures0low60
Jacksonian Seizure0low60
Myoclonic Seizure0low60
Myoclonic Seizures0low60
Non-Epileptic Seizure0low60
Non-Epileptic Seizures0low60
Nonepileptic Seizure0low60
Nonepileptic Seizures0low60
Partial Seizure0low60
Partial Seizures0low60
Petit Mal Convulsion0low60
Seizure0low60
Seizure Disorder0low20
Seizures0low60
Seizures, Auditory0low60
Seizures, Clonic0low60
Seizures, Convulsive0low60
Seizures, Epileptic0low60
Seizures, Focal0low60
Seizures, Generalized0low60
Seizures, Gustatory0low60
Seizures, Motor0low60
Seizures, Olfactory0low60
Seizures, Sensory0low60
Seizures, Somatosensory0low60
Seizures, Tonic0low60
Seizures, Tonic-Clonic0low60
Seizures, Vertiginous0low60
Seizures, Vestibular0low60
Seizures, Visual0low60
Single Seizure0low60
Tonic Clonic Seizure0low60
Tonic Seizure0low60
Tonic Seizures0low60
Tonic-Clonic Seizure0low60
Tonic-Clonic Seizures0low60

Research Highlights

Long-term Use (1)

ArticleYear
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (1)

ArticleYear
Pharmacokinetics of nafimidone in patients with chronic intractable epilepsy.
Clinical pharmacokinetics, Volume: 12, Issue: 6		1987
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

ArticleYear
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]